阿狄科®粪便钙卫蛋白检测试剂盒（1点校准）（酶联免疫法）

【产品名称】
通用名称：阿狄科®粪便钙卫蛋白检测试剂盒（1点校准）（酶联免疫法）
英文名称：IDK® Calprotectin (MRP 8/14) (1-point-calibration) (Stool,1h)
【包装规格】
规格：96人份（复孔检测样本：40个）/盒
测试次数：96（40份样本一式两份）
【预期用途】
用于定量测定粪便中的钙卫蛋白 (MRP 8/14, S100A8/A9)。仅用于体外诊断。

【背景知识】
替代名称：
钙颗粒蛋白 A：MRP8、S100A8、CP-10（在小鼠中）
钙颗粒蛋白 B：MRP14、S100A9
MRP8/14: L1, (p8,14), p34
钙卫蛋白是一种由中性粒细胞和单核细胞产生的钙结合蛋白。面部钙卫蛋白是炎症和肿瘤起源的胃肠道疾病的标志物。
通常很难区分结肠易激和慢性炎症性肠病 (IBD) 患者。这会导致过多不必要的结肠镜检查。使用钙卫蛋白测试，现在可以清楚地区分这两个患者组。

适应症：

• 急性炎症性疾病的炎症标志物
• 评估炎症的严重程度
• 克罗恩病、溃疡性结肠炎或息肉切除后的病程参数

参考文献：
1. D'Haens, G. et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflammatory bowel diseases 18, 2218-24 (2012).
2. Fagerberg, U. L, Loof, L,, Merzoug, R. D, Hansson, L-O. & Finkel, Y. Fecal calprotec-tin levels in healthy children studied with an improved assay. Journal of pediatric gastroenterology and nutrition 37, 468-72 (2003).
3. Fagerhol, M. K. Calprotectin, a faecal marker of organic gastrointestinal abnorma-lity. Lancet 356, 1783- 4 (2000).
4. Hestvik, E. et al. Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based survey. BMC pe-diatrics 11, 9 (2011).
5. Konikoff, M. R. & Denson, L. A. Role of fecal calprotectin as a biomarker of intesti-nal infammation in inflammatory bowel disease. Inflammatory bowel diseases 12,524- 34 (2006).
6. Poullis, A., Foster, R, Northfield, T. C. & Mendall, M. A. Review article: faecal mar-kers in the assessment of activity in inflammatory bowel disease. Alimentary phar-macology & therapeutics 16, 675-81 (2002).
7. Tibble, J. et al. A simple method for assessing intestinal inflammation in Crohn'sdisease. Gut 47, 506-13 (2000).
8. Tibble, J. A., Sigthorsson, G, Bridger, S., Fagerhol, M. K. & Bjarnason, I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with in-flammatory bowel disease. Gastroenterology 119, 15- -22 (2000).
9. Ton, H. et al. Improved assay for fecal calprotectin. Clinica chimica acta; internatio-nal journal of clinical chemistry 292, 41-54 (2000).
10. van Rheenen, P. F., Van de Vijver, E. & Fidler, V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.BMJ (Clinical research ed.) 341, c3369 (2010).
11. Chen, C.-C., Huang, J.-L, Chang, C.J. & Kong, M.-S. Fecal calprotectin as a correla-tive marker in clinical severity of infectious diarrhea and usefulness in evaluating bacterial or viral pathogens in children. Journal of pediatric gastroenterology and nutrition 55, 541-7 (2012).
12. Langhorst, J et al. Non-invasive Marker der Entzundungsaktivitat bei Patienten mit chronisch entzindlichen Darmerkrankungen (CED): Vergleich von Lactofer-rin, Calprotectin, PMN-Elastase im Stuhl, Serum-CRP und klinischen Aktivitatsin-dizes. Zeitschrift fir Gastroenterologie 45, P261 (2007).
13. Schroder, 0., Naumann, M., Shastri, Y., Povse, N. & Stein, J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: com-bination of parameters does not improve diagnostic accuracy of calprotectin. Ali-mentary pharmacology & therapeutics 26, 1035- -42 (2007).